Results 41 to 50 of about 4,521 (200)
MANAGEMENT OF PLEXIFORM NEUROFIBROMA WITH INTERFERON ALPHA
, 2008 Plexiform neurofibroma is a relatively common but potentially devastating manifestation of neurofibromatosis type 1 (NF 1). A substantial number of plexiform neurofibroma causes morbidity. Various treatment modalities are considered to decrease pain.
Memis, Leyla +5 more
core +1 more source
Delayed rectifier K currents in NF1 Schwann cells
Neurobiology of Disease, 2003 K+ (K) currents are related to the proliferation of many cell types and have a relationship to second messenger pathways implicated in regulation of the cell cycle in development and certain disease states.
Lynne A Fieber +3 more
doaj +1 more source
Nail Toxicities Associated With Anticancer Therapies in Children
JEADV Clinical Practice, EarlyView.ABSTRACT Nail toxicities are a frequent yet often underrecognized component of dermatologic adverse events in children receiving anticancer therapies. Both conventional cytotoxic chemotherapy and newer targeted agents can affect the nail matrix, nail bed and periungual tissues, producing a broad spectrum of clinical manifestations that range from ...
Luca Rapparini, Michela Starace
wiley +1 more source
Giant plexiform neurofibroma in neurofibromatosis type 1
, 2018 Giant plexiform neurofibroma in neurofibromatosis type
Lopez, Teresa +3 more
core +1 more source
Selumetinib as a Target Therapy in Progressive Paediatric Low‐Grade Gliomas—Case Series (pLGG)
Journal of Paediatrics and Child Health, EarlyView.ABSTRACT Background Optic pathway gliomas (OPGs) occur in 15%–20% of children with neurofibromatosis type 1 (NF1). While smaller gliomas may be only monitored, the current standard of care for symptomatic ones relies on chemotherapy, most commonly carboplatin and vincristine.
Laura Trapani +12 more
wiley +1 more source
Orbital plexiform neurofibroma and high axial myopia
, 2008 PURPOSE: To report a group of children with neurofibromatosis type 1 and orbital plexiform neurofibroma who developed axial myopia in the associated eye.
Chen, J., Brown, S., Muecke, J.
core +1 more source
The 9th International RASopathies Symposium
American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1934-1941, August 2026.ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel +41 more
wiley +1 more source
Management of advanced laryngeal and hypopharyngeal plexiform neurofibroma in adults
, 2008 Laryngeal neurofibromas are rare. The plexiform subtype is less common and often presents during childhood in association with neurofibromatosis type I.
Dave, Sandeep P +2 more
core +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács +8 more
wiley +1 more source
A case of portal hypertension by presumed as plexiform neurofibroma at the hepatic hilum [PDF]
Clinical and Molecular Hepatology, 2016 Neurofibromas can occur anywhere in the body, but they usually involve the head, neck, pelvis, and extremities. Abdominal visceral involvement is rare, and intrahepatic involvement is even less common.
Kyung Han Lee +11 more
doaj +1 more source